<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01203436</url>
  </required_header>
  <id_info>
    <org_study_id>NICHD-NRN-0010</org_study_id>
    <secondary_id>U10HD027904</secondary_id>
    <secondary_id>U10HD027851</secondary_id>
    <secondary_id>U10HD027856</secondary_id>
    <secondary_id>U10HD027880</secondary_id>
    <secondary_id>U10HD027853</secondary_id>
    <secondary_id>U10HD021415</secondary_id>
    <secondary_id>U10HD040689</secondary_id>
    <secondary_id>U10HD021385</secondary_id>
    <secondary_id>U10HD027871</secondary_id>
    <secondary_id>M01RR000054</secondary_id>
    <secondary_id>M01RR000070</secondary_id>
    <nct_id>NCT01203436</nct_id>
    <nct_alias>NCT00000141</nct_alias>
  </id_info>
  <brief_title>Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity</brief_title>
  <acronym>STOP-ROP</acronym>
  <official_title>Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NICHD Neonatal Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Nursing Research (NINR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Delta Gamma Sorority</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rhea and Raymond White</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Research to Prevent Blindness</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NICHD Neonatal Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial was to determine the efficacy and safety of supplemental
      therapeutic oxygen for infants with prethreshold retinopathy of prematurity (ROP) to reduce
      the probability of progression to threshold ROP and the need for peripheral retinal ablation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retinopathy of prematurity (ROP) is an abnormal growth of the blood vessels in the eye that
      occurs primarily in very premature infants. Eye development occurs normally in the womb; in
      infants born prematurely, however, the blood vessels must finish developing outside the
      protective environment of the uterus. Retinopathy of prematurity (also known as retrolental
      fibroplasia) is a leading cause of blindness and other vision impairments (myopia,
      strabismus, and amblyopia) in children, both in developed and developing countries.

      This study was a randomized trial comparing the effects of 2 oxygenation strategies on the
      progression of ROP. Infants with prethreshold ROP in at least one eye were eligible for the
      study. Enrolled infants were randomized to receive either conventional oxygenation at a pulse
      oximetry target of 89% to 94%, or supplemental oxygen to achieve a pulse oximetry target
      range of 96% to 99%. Infant were placed on continuous pulse oximetry monitoring and to
      maintain oxygen saturation, as much as possible, in the assigned target range.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1994</start_date>
  <completion_date type="Actual">March 1999</completion_date>
  <primary_completion_date type="Actual">March 1999</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression from moderate to severe ROP (prethreshold) to threshold ROP requiring peripheral ablative surgery</measure>
    <time_frame>3 months of age</time_frame>
    <description>Progressing from moderate ROP (prethreshold) to threshold ROP requiring peripheral ablative surgery</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">649</enrollment>
  <condition>Infant, Newborn</condition>
  <condition>Infant, Low Birth Weight</condition>
  <condition>Infant, Small for Gestational Age</condition>
  <condition>Infant, Premature</condition>
  <condition>Retinopathy of Prematurity</condition>
  <condition>Blindness</condition>
  <arm_group>
    <arm_group_label>Supplemental Oxygen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Supplemental oxygen to achieve a pulse oximetry target range of 96% to 99%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Oxygen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional oxygenation at a pulse oximetry target of 89% to 94%.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Supplemental Oxygen Management</intervention_name>
    <description>Supplemental arm with pulse oximetry targeted at 96% to 99% saturation, for at least 2 weeks, and until both eyes were at study endpoints.</description>
    <arm_group_label>Supplemental Oxygen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional Oxygen Management</intervention_name>
    <description>Conventional oxygen arm with pulse oximetry targeted at 89% to 94% saturation.</description>
    <arm_group_label>Conventional Oxygen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants with prethreshold retinopathy of prematurity, confirmed by 2 certified
             ophthalmologic exams

          -  Median pulse oxygen saturation &lt;94% in room air

          -  Median pulse oxygen saturation can be kept safely &gt;96% on oxygen/ventilator

        Exclusion Criteria:

          -  No fatal congenital anomaly or congenital eye anomaly
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>48 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dale L. Phelps, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neal L. Oden, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The EMMES Corporation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cynthia Cole, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard E. McClead, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan R. Spitzer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J. David Bradford, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arkansas Childrens Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles C. Barr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Oh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brown University, Womens and Infants Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara J. Stoll, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James A. Lemons, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David K. Stevenson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward F. Donovan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sheldon B. Korones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tennessee at Memphis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jon E. Tyson, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seetha Shankaran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard A. Ehrenkranz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Easa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kapiolani Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Beverly S. Brozanski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Magee-Womena Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Gordon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tulane University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pamela A. Weber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SUNY Stonybrook</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank W. Kokomoor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Akron Childrens Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael J. Shapiro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raul C. Banagale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Legacy Emanual Childrens Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mitchell E. Stern, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheridan Childrens Healthcare Services</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark W. Preslan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shephen S. Feman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Kirk, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Terri L. Young, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fairview University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mary Anne McCaffree, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Childrens Hospital of Oklahoma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Malini Satish, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Childrens Medical Center of Northwest Ohio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick J. Droste, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cook Institute for Research and Education</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown University, Women &amp; Infants Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://neonatal.rti.org/</url>
    <description>NICHD Neonatal Research Network</description>
  </link>
  <results_reference>
    <citation>Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics. 2000 Feb;105(2):295-310.</citation>
    <PMID>10654946</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2010</study_first_submitted>
  <study_first_submitted_qc>September 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2010</study_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <responsible_party>
    <name_title>Dale L. Phelps/ Lead Principal Investigator</name_title>
    <organization>University of Rochester</organization>
  </responsible_party>
  <keyword>NICHD Neonatal Research Network</keyword>
  <keyword>Very Low Birth Weight (VLBW)</keyword>
  <keyword>Extremely Low Birth Weight (ELBW)</keyword>
  <keyword>Prematurity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Birth Weight</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Retinopathy of Prematurity</mesh_term>
    <mesh_term>Blindness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

